Acurx Pharmaceuticals, Inc. (ACXP) quarterly income statement — complete revenue, gross profit & net income history
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 1.72M | 1.62M | 2.03M | 2.27M | 2.15M | 2.78M | 2.82M | 4.12M | 4.38M | 5.11M | 3.11M | 3.45M | 2.9M | 3.26M | 3.54M | 2.62M | 2.67M | 2.63M | 4.64M | 4.07M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.37B | 6.25B | 1.6M | 1.75M | 1.55M | 1.96M | 1.62M | 2.3M | 2.82M | 3.17M | 1.77M | 1.71M | 1.89M | 1.83M | 1.95M | 1.71M | 1.85M | 1.91M | 3.52M | 3.98M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 341.47K | 1.83B | 429.69K | 524.21K | 598.8K | 825.06K | 1.2M | 1.83M | 1.56M | 1.94M | 1.35M | 1.74M | 1.02M | 1.43M | 1.59M | 911.69K | 818.89K | 716.22K | 1.13M | 95.07K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.72M | -1.62M | -2.03M | -2.27M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4.07M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 20.16% | 41.87% | 28.1% | 44.95% | 50.91% | 45.61% | 9.42% | -19.66% | -50.81% | -56.86% | 12.05% | -31.47% | -8.72% | -24.11% | 23.71% | 35.62% | -81.11% | -140.35% | - | - |
| EBITDA | -1.72M | -1.62M | -2.03M | -2.27M | 0 | 0 | 0 | -4.12M | -4.38M | 0 | 0 | 0 | -2.9M | 0 | 0 | 0 | -2.67M | 0 | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | - | 44.95% | 100% | - | - | - | -50.81% | - | - | - | -8.72% | - | - | - | - | 100% | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 2.15M | 2.78M | 2.82M | 0 | 0 | 5.11M | 3.11M | 3.45M | 0 | 3.26M | 3.54M | 2.62M | 0 | 2.63M | 4.64M | 4.07M |
| EBIT | -1.72M | -1.62M | -2.03M | -2.27M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4.07M |
| Net Interest Income | 35.01K | 38.84K | 35.91K | 23.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 35.01K | 38.84K | 35.91K | 23.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 35.01K | 38.84K | 35.91K | 23.4K | 0 | 0 | 0 | 782 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.5K |
| Pretax Income | -1.68M | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.68M | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 21.79% | 43.26% | 29.37% | 45.5% | 50.91% | 45.61% | 9.42% | -19.64% | -50.81% | -56.86% | 12.05% | -31.47% | -8.72% | -24.11% | 23.71% | 34.55% | -81.11% | -140.35% | - | - |
| Net Income (Continuing) | -1.68M | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.12 | -0.67 | -1.23 | -1.89 | -2.14 | -3.27 | -3.45 | -5.21 | -5.66 | -7.60 | -4.79 | -5.60 | -5.00 | 3.60 | -6.40 | -5.20 | -5.20 | -7.60 | -9.20 | -11.40 |
| EPS Growth % | 47.66% | 79.51% | 64.35% | 63.72% | 62.19% | 56.97% | 27.97% | 6.96% | -13.2% | -311.11% | 25.16% | -7.69% | 3.85% | 147.37% | 30.43% | 54.39% | -73.33% | -245.45% | - | - |
| EPS (Basic) | -1.12 | -0.67 | -1.23 | -1.89 | -2.14 | -3.27 | -3.45 | -5.21 | -5.66 | -7.60 | -4.79 | -5.60 | -5.00 | 3.60 | -6.40 | -5.20 | -5.20 | -5.20 | -9.20 | -11.40 |
| Diluted Shares Outstanding | 1.5M | 1.5M | 1.63M | 1.19M | 1M | 851.55K | 818.15K | 791.25K | 773.65K | 673.1K | 650.25K | 609.3K | 581.95K | 580.3K | 557.4K | 513.15K | 511.65K | 511.23K | 505.8K | 348.4K |
| Basic Shares Outstanding | 1.5M | 1.5M | 1.63M | 1.19M | 1M | 851.55K | 818.15K | 791.25K | 773.65K | 673.1K | 650.25K | 609.3K | 581.95K | 580.3K | 557.4K | 513.15K | 511.65K | 511.23K | 505.8K | 348.4K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |